• Study Resource
  • Explore
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
treatment of gastrointestinal ulcers
treatment of gastrointestinal ulcers

... the risk of GI ulceration in animals predisposed to ulcer formation.  Cytoprotective agents include antacids and sucralfate. Antacids are weak bases that neutralize gastric acid within the stomach lumen; they may also promote gastric prostaglandin production. ...
Virus-host interactomics: new insights and opportunities for antiviral drug discovery
Virus-host interactomics: new insights and opportunities for antiviral drug discovery

... typically divided into two technical steps consisting of the capture of cellular proteins with the bait protein and identification of affinity-purified proteins by mass spectrometry (MS; method reviewed in [86]). (c) The protein array. Functional protein arrays, also called ‘protein chips’, can comp ...
Document
Document

... Garcia, R. A.; Forde, C. A.; Godwin, H. A. Proc. Natl. Acad. Sci. U.S.A. ...
汤慧芳_大环内酯类&林可霉素
汤慧芳_大环内酯类&林可霉素

... site on the 50S bacterial ribosome, forming a stable ternary complex. Thus,they synergistically interrupt protein synthesis. The combination drug is bactericidal and has a long postantibiotic effect. ...
TEXT: Basic and Clinical Pharmacology by
TEXT: Basic and Clinical Pharmacology by

... RATIONAL: To present current information on drugs that is important for rational drug therapy. COURSE OBJECTIVES: Students will be able to 1) Discuss drugs used in the prevention, treatment and maintenance therapy of various diseases and medical conditions. 2) Discuss effects of different classes of ...
ICAAC Chicago, IL September 14-17, 2003
ICAAC Chicago, IL September 14-17, 2003

... International AIDS Society Conference in July 2003 Baseline viral load? – Although failure rates higher in those with > 100,000, still significant in lower viral loads[1] PK interaction? – No serum interaction between ABC and TDF[2] – Possible intracellular interaction(s) being investigated QD abaca ...
Physical and Chemical Methods of Disinfection and Sterilization
Physical and Chemical Methods of Disinfection and Sterilization

... as early as possible and continue treatment long enough to ensure eradication of infection, but give an antimicrobial drug only when it is indicated by rational choice. ...
DNA Replication
DNA Replication

... joints, skin, and soft tissues. It is eliminated mostly by renal clearance. • Newer derivatives Grepafloxacin, Levofloxacin, Gatifloxacin, Clinafloxacin Moxifloxacin, Trovafloxacin can have increased activity against gram (+) and anaerobic bacteria, but are not generally first line drugs for these o ...
Competitive advantage
Competitive advantage

... • This has recently been proved by Novartis in a phase IIa POC study. • No other competing projects identified in clinical development. *Datamonitor, Epidatabase (2003) **IMS Data ...
Nucleic acid based therapeutic molecules
Nucleic acid based therapeutic molecules

... majority of pharmaceutical drugs available today comprise of small organic molecules, peptides or proteins (e.g. hormones), and antibodies which typically bind to target proteins directly to inhibit or modulate the functions of proteins. So, for the last decade or so, researchers have tried to creat ...
NSAIDs not 4 322
NSAIDs not 4 322

...  First choice in inflammatory joint diseases. Naproxen:  Related to ibuprofen. More potent. Moderate risk of side effects, longer acting Diclofenac: (Voltaren)  It is very potent used in:  Rheumatoid arthritis and osteoarthritis  Renal colic and postoperative pain Indomethacin (Indocid)  Poten ...
Chapter 12 Antimicrobial Therapy Antibiotics
Chapter 12 Antimicrobial Therapy Antibiotics

... • Amphotericin B - binds to ergosterol found in fungi and protozoa, but not in human cells - increases membrane permeability • Side effects are numerous due to toxicity ...
Syllabus - University of Minnesota College of Pharmacy
Syllabus - University of Minnesota College of Pharmacy

... derangements that lead to cellular malfunction and disease and the rationale of novel targeting in drug development and how these apply to clinical pharmacology. 3. Understand gene regulation and its impact on enzyme activity, signal transduction pathways and tissue specialization and relate genetic ...
Sean W. Fanning, Ph.D.
Sean W. Fanning, Ph.D.

... “Structural basis for an engineered dual-specific antibody: conformational diversity leads to an unconventional metal binding site.” And I co-authored a paper in Protein Science named “A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches.” I was invite ...
Small Changes are Big Steps: Making Nanotechnologies Ethically
Small Changes are Big Steps: Making Nanotechnologies Ethically

... novel treatment combining at least three drugs, the High Activity Antiretroviral Therapy (HAART), was introduced more than a decade ago. Antiretroviral (ARV) doses are high and complicated regimes impact patients´ lifestyle. According to epidemiological investigations, adherence levels below 95% dra ...
Journal about antidepressant drugs U.N 42904891 Date:18
Journal about antidepressant drugs U.N 42904891 Date:18

... Have a family or personal history of successful treatment with MAOIs ...
HTN Meds Alpha 2 agonists Side effects Alpha 1 adrenergic
HTN Meds Alpha 2 agonists Side effects Alpha 1 adrenergic

... † Currently 10 ACE Inhibitors on the market. ...
INHIBITOR of BACTERIAL PROTEIN SYNTHESIS
INHIBITOR of BACTERIAL PROTEIN SYNTHESIS

... • They are important drugs for the treatment of serious infections caused by aerobic gr(-) bacteria • When used alone they are not reliably effective in the treatment of gr(+) cocci • Antibacterial synergy may occur with the combination of wall synthesis inhibitors • Streptomycintuberculosis • Spec ...
Document
Document

... freedom to tilt and twist at b’-a’, constrained to a specific twist mode at a-b, and with no freedom to twist at b-b’. Two active sites can approach much more closely than is found in crystal structures – and indeed hinge motion to bring these sites into proximity is the lowest energy normal mode of ...
Binding of Daunomycin to DNA and the Inhibition of RNA and DNA
Binding of Daunomycin to DNA and the Inhibition of RNA and DNA

... 7.5, and suspended in 10 volumes of 10 mr@iTris:l m@i polymerase. After standing for 5 mm at room temperature, EDTA:l0 mM NaCI, pH 7.5. After 10 mm, the cells were the mixture was filtered through Millipore (Type HA, Milli homogenized with 25 strokes of the Dounce homogenizer. pore Corp., Bedford, M ...
Media Release
Media Release

... proviruses. The low levels of active P-TEFb and the cytoplasmic sequestration of NF-κB in resting infected cells largely contribute to maintenance of HIV-1 latency. Therefore, utilization of chemical compounds that target both pathways may lead to more potent effects on HIV-1 reactivation than the e ...
Tutorial NSAIDs
Tutorial NSAIDs

... RELATED TO HIGH DOSES ...
Table 2 - Bahrain Medical Bulletin
Table 2 - Bahrain Medical Bulletin

... protease inhibitor2. Monotherapy should be avoided because it is clearly inferior to combination therapies. Also, the use of dual NRTI-only containing regimens should be avoided because initial viral suppression may not be sustained8,9,19,20. Two types of initial HAART strategies – NNRTI or PI-based ...
STATEMENT OF JOHN ERICKSON, PhD
STATEMENT OF JOHN ERICKSON, PhD

... in circulation longer. Since it inhibits the same metabolic enzymes that are responsible for breaking down and eliminating many other drugs, including competitors’ protease inhibitors, co-administration of Norvir with these drugs can lead to higher than normal blood levels and prolonged circulation ...
View/Open - University of Khartoum
View/Open - University of Khartoum

... drawback in the sense that risk of developing prostate cancer is positively associated with the chlordecone concentration in blood [36]. Parthenolide showed a higher probability to function as TP53 expression enhancer (Pa = 0.980). TP53 helps protect genome integrity and maintain general cell homeos ...
< 1 ... 49 50 51 52 53 54 55 56 57 ... 66 >

Discovery and development of integrase inhibitors

The first human immunodeficiency virus (HIV) case was reported in the United States in the early 1980s. Many drugs have been discovered to treat the disease but mutations in the virus and resistance to the drugs make development difficult. Integrase is a viral enzyme that integrates retroviral DNA into the host cell genome. Integrase inhibitors are a new class of drugs used in the treatment of HIV. The first integrase inhibitor, raltegravir, was approved in 2007 and other drugs were in clinical trials in 2011.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report